Health Care·Biotechnology·$6.4B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $3.26 | N/A | +29.88% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $3.26 | N/A | +29.88% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management expressed satisfaction with the EPS results, highlighting their commitment to pipeline development. However, they did not provide any forward guidance.
We are pleased with our EPS performance this quarter.
Our focus remains on advancing our pipeline.
Protagonist Therapeutics reported a strong EPS performance, beating expectations significantly. However, the stock reacted negatively, dropping 1.04%. The lack of revenue data and forward guidance may have contributed to investor uncertainty.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
AECOM
May 6, 2024